DermTech Inc

DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in La Jolla, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

DermTech sees growth in test volumes despite revenue decline

DermTech's Q4 performance reflects growth in coverage and billable sample volumes, despite a decline in total revenue.
The company's strengths lie in expanding market acceptance, stabilized ASPs, and efforts to reduce payer friction.
Challenges include revenue diversification, leadership transition, and uncertainties in ASP trends, while opportunities exist in payer discussions and operational enhancements.

DermTech Inc reports revenue growth and volume increases in Q1

DermTech Inc's Q1 2023 performance showed revenue growth and volume increases, with a focus on stabilizing ASP and driving reimbursed volumes.
While facing challenges with flat DMT volumes and frustration over national payers' views, the company is optimistic about broader acceptance and cost-saving initiatives.
Opportunities lie in TRUST 2 study results influencing payer discussions, momentum with other payers, and targeting physicians with aligned payer mixes.

DermTech reports mixed Q2 results, focuses on revenue growth

DermTech faces challenges with flat DMT volumes and higher operating expenses but is leveraging strengths in insurance partnerships and revenue prioritization.
Opportunities lie in the growth potential of the DMT, expanding coverage, and optimizing sales strategies for revenue enhancement.
Overall, DermTech's financial performance in Q2 2023 reflects a strategic focus on revenue growth amidst operational challenges.

DermTech reports improved Q3 performance, eyes TRUST 2 study impact

DermTech's Q3 2023 performance showcased positive trends in ASP, revenue, and operational efficiency, despite a net loss.
Strategic strengths in sales team alignment, clinical value emphasis, and liquidity position the company well for future growth.
Challenges lie in maintaining test volumes, sustaining margins, and addressing cost reductions and effective payer communications.
Opportunities include TRUST 2 study results, legislative efforts, and focusing on reimbursed tests for revenue growth.

DermTech Inc reports robust Q4 growth and strategic cost reductions

DermTech Inc's Q4 2023 performance showcased strong growth in key metrics and financial health.
The company's focus on precision genomics and cost efficiencies positions it well for future success.
Challenges lie in sustaining revenue growth, optimizing expenses, and engaging payers effectively.
Opportunities abound in expanding reimbursed tests, revenue, and market presence for long-term growth.

The full company name is Design Media Technology, Inc.

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its membership in the Corporate Council of the Pediatric Dermatology Research Alliance (PeDRA). PeDRA is a nonprofit research network with the mission to create, inspire and sustain research to prevent, treat and cure childhood skin disease by bringing together pediatric dermatologists for organized st

DermTech Joins PeDRA Corporate Council, Supporting Efforts to Address Pediatric Skin Diseases

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that its chief medical officer, Dr. Loren Clarke, will present study data illustrating how genomic technology can enhance melanoma detection and improve patient care at America's Health Insurance Plans (AHIP) 2022. The meeting is being held from June 21-23, 2022 in Las Vegas, Nev. “Across the spectrum

DermTech to Present on Genomic Innovation in Dermatology at AHIP 2022

DermTech (DMTK) has transformative solutions that are more effective and accurate than traditional biopsy-based diagnostic approaches for detecting Skin Cancer. Commercialization of its proprietary SmartSticker solution has been slow, despite recent significant investments in the company's salesforce.

DermTech: Approaching An All Or Nothing Moment

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that management is scheduled to present at the William Blair Growth Stock Conference on Wednesday, June 8, 2022 at 2:00 p.m. CT. A live webcast of the presentation will be available on the investor relations section of DermTech's website at https://investors.dermtech.com/news-events/events. A replay of

DermTech to Present at the William Blair Growth Stock Conference

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it is sponsoring The Sun Bus, a community service provided by the Colorado Melanoma Foundation in partnership with Epiphany Dermatology, to bring free skin cancer screenings and public education to communities across the U.S. The Sun Bus is a mobile screening station and sun safety classroom that

DermTech Sponsors The Sun Bus to Bring Free Skin Cancer Screenings to More Than 50 Locations Across the U.S.

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its presentation at the Society for Investigative Dermatology's (SID) annual meeting, held from May 18-21, 2022 in Portland, OR. Michael Howell, Ph.D., chief scientific officer at DermTech, presented new research that enables the differentiation of the inflammatory signatures of atopic dermatitis from

DermTech Presents New Research Differentiating Atopic Dermatitis and Psoriasis at the Society for Investigative Dermatology's Annual Meeting

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the return of its #Stickit2Melanoma campaign in honor of Melanoma and Skin Cancer Awareness Month. First launched in 2021, the campaign supports DermTech's core mission to help end deaths from melanoma, one of the deadliest forms of skin cancer, through early and reliable detection. The #Stickit2Melano

DermTech Kicks Off Second Annual #Stickit2Melanoma Campaign, Raising Awareness for Melanoma and the Importance of Skin Exams

DermTech, Inc. (NASDAQ:DMTK ) Q1 2022 Earnings Conference Call March 3, 2022 5:00 PM ET Company Participants John Dobak – President and Chief Executive Officer Kevin Sun – Chief Financial Officer Steve Kunszabo – Senior Director Investor Relations Conference Call Participants Brian Weinstein – William Blair Stephanie Iannetta – Cowen & Company Alexander Nowak – Craig-Hallum Capital Thomas Flaten – Lake Street Capital Markets Jacob Johnson – Stephens Inc. Operator Good day, and thank you for standing by. And welcome to DermTech's First Quarter 2022 Financial Results Call.

DermTech, Inc. (DMTK) CEO John Dobak on Q1 2022 Results - Earnings Call Transcript

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -18.82% and 1.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

DermTech, Inc. (DMTK) Reports Q1 Loss, Misses Revenue Estimates

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its first-quarter 2022 financial results and affirmed its full-year 2022 outlook. “We kicked off the year on a record pace for many of our key operating metrics and affirmed our full-year 2022 outlook,” said John Dobak, M.D., CEO, DermTech. “We also added a payor contract during the first quarter bringi

DermTech Reports First-Quarter 2022 Financial Results; Company Affirms Full-Year 2022 Outlook

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the publication of “Noninvasive Genomic Characterization of Patients with Nonsclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease Identified a Novel Gene Signature in Responders to Ruxolitinib Cream,” in Transplantation and Cellular Therapy. Graft versus host disease (GvHD)

DermTech Announces Publication of New GvHD Clinical Research Conducted in Collaboration with Memorial Sloan Kettering Cancer Center

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the expansion of access to its telehealth application, DermTech Connect, from eight states to 44 states, encompassing approximately 95% of the U.S. population. The mobile app provides improved access to an independent dermatologist, allowing users to choose when to have a mole evaluated by a dermatolog

DermTech Expands Telehealth Application, DermTech Connect, Across 44 States

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it is participating in San Diego nonprofit Connect's inaugural Five.Ten.Thirty event. Taking place on April 28, 2022 at Petco Park, the gathering is a celebration of San Diego's first annual ‘Innovation Day,' recently declared by Mayor Todd Gloria. The event will bring together the city's most inn

DermTech to Showcase DermTech Stratum, an Expanded Translational Medicine Service Offering, at San Diego's Inaugural ‘Innovation Day' Event

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Tuesday, May 3, 2022 at 5:00 p.m. Eastern Time (ET) to discuss the Company's first-quarter 2022 operating and financial highlights. In advance of the call on May 3, 2022, DermTech will issue its first-quarter 2022 earnings press release. To participate in the teleconference,

DermTech Announces Release Date for First-Quarter 2022 Financial Results

ZUG, Switzerland & NEW YORK--(BUSINESS WIRE)--CasperLabs, a leading blockchain software company for the enterprise market, is pleased to announce that Michael Dobak has been appointed to the position of chief marketing officer. Mr. Dobak will have worldwide responsibility for the visibility, reputation and growth of the CasperLabs brand. Additionally, he is responsible for marketing initiatives targeting enterprise companies and the community of developers who are rapidly adopting blockchain. M

CasperLabs Appoints Michael Dobak as Company's First Chief Marketing Officer to Drive Business Adoption of Blockchain Technology

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN: The Journal of Cutaneous Medicine has published its original research study, with Daniel M. Siegel, MD, MS as the lead author. A nationally recognized reimbursement expert, Dr. Siegel is a clinical professor of dermatology at SUNY Downstate Medical Center and a former president of the Americ

DermTech Study, “Cost-Benefit Analysis of the Pigmented Lesion Assay When Introduced into the Visual Assessment / Histopathology Pathway for Lesions Clinically Suspicious for Melanoma,” Published in SKIN: The Journal of Cutaneous Medicine

DermTech, Inc.'s (DMTK) CEO John Dobak on Q4 2021 Results - Earnings Call Transcript

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -20.55% and 5.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

DermTech, Inc. (DMTK) Reports Q4 Loss, Lags Revenue Estimates

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported financial results as of and for the quarter and fiscal year ended December 31, 2021. Fourth Quarter and Full Year 2021 Highlights Billable sample volume of approximately 11,780 for the fourth quarter of 2021, a 42% increase compared to approximately 8,300 recorded for the fourth quarter of 2020. Billable sample volume f

DermTech Reports Fourth Quarter and Full Year 2021 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management will present at the following upcoming conferences: Cowen 42nd Annual Health Care Conference Presenting on Tuesday, March 8, 2022 at 12:50 p.m. Eastern Time Oppenheimer 32nd Annual Healthcare Conference Presenting on Tuesday, March 15, 2022 at 3:20 p.m. Eastern Time Interested parties may access the

DermTech Management to Present at Upcoming Investor Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the addition of Adelle Walker to the organization as Vice President of Consumer Products. Walker takes on this new role as DermTech further invests in bringing its precision genomics platform to the skin health and wellness categories. Walker brings more than 20 years of experience to DermTech, having

DermTech Welcomes Adelle Walker as Vice President of Consumer Products

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it plans to release its fourth quarter and full-year 2021 financial results after the market closes on Tuesday, March 1, 2022. In conjunction with such release, the Company plans to host a conference call and webcast that day at 1:30 p.m. Pacific time / 4:30 p.m. Eastern time to discuss its financial results and r

DermTech to Announce Fourth Quarter and Full-Year Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management will participate at the following conferences: 11th Annual SVB Leerink Global Healthcare Conference Participating in investor meetings on February 16-17, 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Presenting on Wednesday, February 16, 2022 at 1:00 p.m. Eastern

DermTech Management to Participate in Upcoming Investor Conferences

GoodRx Holdings

It may depend on the underlying premise of what the company is all about.

Should You Sell DermTech and GoodRx Stocks Right Now?

Doximity

These two stocks could provide life-changing returns in 10 years.

News for DermTech Inc Stock (DMTK)